Skillman, NJ, United States of America

Katerina Leftheris

Average Co-Inventor Count = 5.8

ph-index = 14

Forward Citations = 724(Granted Patents)

Forward Citations (Not Self Cited) = 581(Sep 21, 2024)

DiyaCoin DiyaCoin 0.83 

Inventors with similar research interests:


Location History:

  • Princeton, NJ (US) (2008)
  • Killman, NJ (US) (2014)
  • Skillman, NJ (US) (1999 - 2015)
  • San Diego, CA (US) (2013 - 2021)
  • San Mateo, CA (US) (2020 - 2024)
  • South San Francisco, CA (US) (2022 - 2024)


Years Active: 1999-2024

where 'Filed Patents' based on already Granted Patents

89 patents (USPTO):
3 patents (CIPO):

Certainly! Here is the article about the inventor Katerina Leftheris:

Title: Innovator Spotlight: Katerina Leftheris

Introduction:

Katerina Leftheris, a prolific inventor based in Skillman, NJ, is renowned for his groundbreaking work in the field of pharmaceuticals. With an impressive portfolio of 87 patents, Leftheris has made significant contributions to the development of novel compounds for the treatment of debilitating conditions such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Latest Patents:

Leftheris' latest patents include innovative amino acid compounds with unbranched linkers, designed as integrin inhibitors for treating fibrosis. These compounds, represented by formulas (A) and (I), have shown promising results in the management of IPF and NSIP. His work underscores a commitment to advancing therapeutic options for patients grappling with these challenging diseases.

Career Highlights:

Throughout his career, Katerina Leftheris has held key positions at prominent pharmaceutical companies, including Bristol-Myers Squibb Company and Vitae Pharmaceuticals, Inc. His expertise and inventive spirit have been instrumental in driving forward research and development initiatives aimed at addressing unmet medical needs and enhancing patient outcomes.

Collaborations:

Leftheris has collaborated closely with esteemed colleagues such as Stephen T. Wrobleski and Chunjian Liu, pooling their collective expertise to push the boundaries of pharmaceutical innovation. Together, they have fostered a culture of excellence and teamwork, culminating in the successful creation of transformative compounds that have the potential to revolutionize the treatment landscape for fibrotic disorders.

Conclusion:

In conclusion, Katerina Leftheris stands as a visionary inventor at the forefront of pharmaceutical innovation. His dedication to translating scientific discoveries into tangible solutions for patients underscores a commitment to excellence and compassion. As he continues to push the boundaries of scientific knowledge, Leftheris's impact on the field of medicine is sure to be enduring and far-reaching.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…